Jacobs Levy Equity Management Inc. Cuts Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)

Jacobs Levy Equity Management Inc. lowered its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 93.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,261 shares of the company’s stock after selling 262,010 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in Design Therapeutics were worth $113,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. American Century Companies Inc. raised its stake in Design Therapeutics by 19.9% during the fourth quarter. American Century Companies Inc. now owns 39,115 shares of the company’s stock worth $241,000 after purchasing an additional 6,481 shares during the period. JPMorgan Chase & Co. increased its position in shares of Design Therapeutics by 186.9% in the third quarter. JPMorgan Chase & Co. now owns 40,687 shares of the company’s stock worth $219,000 after acquiring an additional 26,503 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Design Therapeutics by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 264,675 shares of the company’s stock worth $1,633,000 after acquiring an additional 7,243 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Design Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 761,640 shares of the company’s stock worth $4,700,000 after acquiring an additional 3,090 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Design Therapeutics by 4.7% in the fourth quarter. Rhumbline Advisers now owns 52,932 shares of the company’s stock worth $327,000 after acquiring an additional 2,365 shares in the last quarter. Hedge funds and other institutional investors own 56.64% of the company’s stock.

Design Therapeutics Stock Up 4.5%

Design Therapeutics stock opened at $3.51 on Monday. Design Therapeutics, Inc. has a 52-week low of $2.60 and a 52-week high of $7.77. The firm has a fifty day moving average of $3.88 and a 200-day moving average of $4.88. The firm has a market capitalization of $199.26 million, a P/E ratio of -4.13 and a beta of 1.77.

Design Therapeutics (NASDAQ:DSGN) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, research analysts expect that Design Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.